Results 151 to 160 of about 284,617 (309)
Diagnostic reasoning in neurogenetics: a general approach. [PDF]
Fussiger H, Pedroso JL, Saute JAM.
europepmc +1 more source
From symptoms to causes: Diversity effects in diagnostic reasoning [PDF]
Nancy S. Kim, Frank C. Keil
openalex +1 more source
Diagnostic Reasoning Prompts Reveal the Potential for Large Language Model Interpretability in Medicine [PDF]
Thomas Savage +4 more
openalex +1 more source
Chemoresistance in bladder cancer: Macrophage recruitment associated with CXCL1, CXCL5 and CXCL8 expression is characteristic of Gemcitabine/Cisplatin (Gem/Cis) Non‐Responder tumors (right side) while Responder tumors did not show substantial tumor‐stromal crosstalk (left side). All biological icons are attributed to Bioicons: carcinoma, cancerous‐cell‐
Sophie Leypold +11 more
wiley +1 more source
An analysis of physicians' diagnostic reasoning regarding pediatric abusive head trauma. [PDF]
Hymel KP +12 more
europepmc +1 more source
ABSTRACT Objective Cognitive impairment, fatigue, and depression are common in multiple sclerosis (MS), potentially due to disruption of regional functional connectivity caused by white matter (WM) lesions. We explored whether WM lesions functionally connected to specific brain regions contribute to these MS‐related manifestations.
Alessandro Franceschini +7 more
wiley +1 more source
ABSTRACT Background Poststroke fatigue (PSF) and frailty share substantial overlap in their manifestations, yet previous research has yielded conflicting results due to the use of heterogeneous frailty assessment tools. Objective To evaluate the independent impact of frailty on PSF using a unified measurement system (Tilburg Frailty Indicator, TFI ...
Chuan‐Bang Chen +6 more
wiley +1 more source
Diagnostic Reasoning by Expert Clinicians: What Distinguishes Them From Their Peers? [PDF]
Kumar B, Ferguson K, Swee M, Suneja M.
europepmc +1 more source
ABSTRACT Objective Facioscapulohumeral muscular dystrophy type 1 (FSHD1) is a progressive neuromuscular disorder with no approved treatments. Identifying reliable biomarkers is critical to monitor disease severity, activity, and progression. Interleukin‐6 (IL‐6) has been proposed as a candidate biomarker, but longitudinal validation is limited ...
Jonathan Pini +13 more
wiley +1 more source

